Stephen Mandel
Lone Pine Capital
Stephen Mandel JAZZ PHARMACEUTICALS PLC stake
total: 304
Lone Pine Capital JAZZ trades
- Total transactions:
- 6
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 3
- Held since:
- 2014 Q1
- Held for:
- 5 quarters
- Latest activity:
- 2015 Q2
According to 2026 Q2 report, Stephen Mandel doesn't hold any JAZZ PHARMACEUTICALS PLC (JAZZ) shares. To date, the estimated cost basis is nearly $139.66 for "buy" trades and estimated average "sell" price is $168.58. Lone Pine Capital first purchased JAZZ in 2014 Q1, initially acquiring about 2.34M shares. Since the initial investment in JAZZ PHARMACEUTICALS PLC (JAZZ), Lone Pine Capital has made 5 more transactions.
When did Stephen Mandel sell JAZZ PHARMACEUTICALS PLC (JAZZ)?
Stephen Mandel sold off the entire JAZZ PHARMACEUTICALS PLC (JAZZ) position in 2015 Q2.
When did Stephen Mandel buy JAZZ PHARMACEUTICALS PLC (JAZZ)?
Stephen Mandel first invested in JAZZ PHARMACEUTICALS PLC (JAZZ) in 2014 Q1 at the reported quarter-end price of $138.68 per share.
What's the cost basis of Lone Pine Capital's JAZZ stake?
The estimated cost basis for JAZZ PHARMACEUTICALS PLC (JAZZ) stake is around $139.66 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $139.66
- Weighted AVG sell price:
- $168.58
Stephen Mandel's historical trades in JAZZ PHARMACEUTICALS PLC
6 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2015 Q2
|
0.00%
|
$172.79
|
-100% (-260,985)
|
|||
|
2015 Q1
|
0.19%
|
$172.79
|
-86.14% (-1,622,669)
|
|||
|
2014 Q4
|
1.32%
|
$163.73
|
+5.31% (+95,047)
|
|||
|
2014 Q3
|
1.15%
|
$160.56
|
-14.30% (-298,520)
|
|||
|
2014 Q2
|
1.28%
|
$147.01
|
-10.98% (-257,359)
|
|||
|
2014 Q1
|
1.46%
|
$138.68
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.